Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.

Gross ME, Leichman L, Lowe ES, Swaisland A, Agus DB.

Cancer Chemother Pharmacol. 2012 Jan;69(1):273-80. doi: 10.1007/s00280-011-1757-y. Epub 2011 Oct 15.

PMID:
22002543
2.

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.

Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, Cantarini M, Macpherson M, Swaisland A, Swaisland H, Twelves C.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1485-95. doi: 10.1007/s00280-011-1611-2. Epub 2011 Apr 13.

PMID:
21487718
3.

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Baselga J, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J.

Clin Cancer Res. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. Epub 2010 Aug 30.

4.

Effects of the Src inhibitor saracatinib (AZD0530) on renal function in healthy subjects.

Dalton RN, Chetty R, Stuart M, Iacona RB, Swaisland A.

Anticancer Res. 2010 Jul;30(7):2935-42.

PMID:
20683035
5.

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.

Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD, Eastell R.

J Bone Miner Res. 2010 Mar;25(3):463-71. doi: 10.1359/jbmr.090830. Erratum in: J Bone Miner Res. 2012 Jun;27(6):1435.

6.

Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.

Chhun S, Verstuyft C, Rizzo-Padoin N, Simoneau G, Becquemont L, Peretti I, Swaisland A, Wortelboer R, Bergmann JF, Mouly S.

Br J Clin Pharmacol. 2009 Aug;68(2):226-37. doi: 10.1111/j.1365-2125.2009.03438.x.

7.

Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?

Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Mark Hickinson D, Swaisland A.

Anticancer Drugs. 2009 Nov;20(10):856-66. doi: 10.1097/CAD.0b013e32833034e1. Review.

PMID:
19657272
8.

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

Stewart JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE.

J Clin Oncol. 2009 Apr 10;27(11):1864-71. doi: 10.1200/JCO.2008.17.0530. Epub 2009 Mar 16. Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410.

PMID:
19289630
9.

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.

Chau I, Cunningham D, Hickish T, Massey A, Higgins L, Osborne R, Botwood N, Swaisland A.

Ann Oncol. 2007 Apr;18(4):730-7. Epub 2007 Jan 20.

PMID:
17237473
10.

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.

Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE 2nd, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8.

11.

The effects of a selective 5-HT2 receptor antagonist (ICI 170,809) on platelet aggregation and pupillary responses in healthy volunteers.

Millson DS, Jessup CL, Swaisland A, Haworth S, Rushton A, Harry JD.

Br J Clin Pharmacol. 1992 Mar;33(3):281-8.

12.

The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide.

Laher MS, Mulkerrins E, Hosie J, Connell PA, Smith RP, Swaisland AJ.

J Hum Hypertens. 1991 Dec;5 Suppl 2:77-84.

PMID:
1665183
13.

The pharmacokinetics of co-administered lisinopril and hydrochlorothiazide.

Swaisland AJ.

J Hum Hypertens. 1991 Dec;5 Suppl 2:69-71.

PMID:
1665181
14.

The metabolic disposition of an orally active pyridyl thiadiazinone cardiotonic agent (MPTD) in rat and baboon.

McKillop D, Pickup KJ, Swaisland AJ, Holmes BF.

Xenobiotica. 1990 Apr;20(4):401-15.

PMID:
2346037
15.

Human pharmacokinetics of temocillin (BRL 17421) side chain epimers.

Guest EA, Horton R, Mellows G, Slocombe B, Swaisland AJ, Tasker TC.

J Antimicrob Chemother. 1985 Mar;15(3):327-36.

PMID:
3997707
16.

Human pharmacokinetics and antimicrobial activities of the temocillin epimers.

Guest EA, Horton R, Mellows G, Slocombe B, Swaisland AJ, Tasker TC, White AR.

Drugs. 1985;29 Suppl 5:154-61.

PMID:
4029021
17.

Effect of renal function and dialysis on temocillin pharmacokinetics.

Boelaert J, Daneels R, Schurgers M, Mellows G, Swaisland AJ, Lambert AM, Van Landuyt HW.

Drugs. 1985;29 Suppl 5:109-13.

PMID:
4029012
18.

The pharmacokinetics of temocillin in patients with normal and impaired renal function.

Boelaert J, Daneels R, Schurgers M, Lambert AM, Van Landuyt HW, Mellows G, Wolf J, Swaisland AJ.

J Antimicrob Chemother. 1983 Apr;11(4):349-56.

PMID:
6853404
19.

Determination of therapeutic concentrations of indoramin by liquid chromatography with fluorimetric detection.

Swaisland AJ.

Analyst. 1981 Jun;106(1263):717-9. No abstract available.

PMID:
7258656
20.

The biotransformation of ciclazindol in man.

Swaisland AJ, Franklin RA, White AC.

Br J Clin Pharmacol. 1979 Jan;7(1):120-3. No abstract available.

21.

The disposition of a novel pyrimidoindole, ciclazindol, in the rat and patas monkey.

Swaisland AJ, Pierce DM, Franklin RA.

Drug Metab Dispos. 1977 Sep-Oct;5(5):419-24. No abstract available.

PMID:
20289
22.

The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers.

Swaisland AJ, Franklin RA, Southgate PJ, Coleman AJ.

Br J Clin Pharmacol. 1977 Feb;4(1):61-5.

23.

Pharmacokinetic studies on WY 23409 HCl.

Swaisland AJ, Franklin RA, Southgate RJ.

Br J Clin Pharmacol. 1975 Oct;2(5):473-4. No abstract available.

24.

Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide.

Sims P, Grover PL, Swaisland A, Pal K, Hewer A.

Nature. 1974 Nov 22;252(5481):326-8. No abstract available.

PMID:
4473724
25.

Reactions of polycyclic hydrocarbon epoxides with RNA and polyribonucleotides.

Swaisland AJ, Grover PL, Sims P.

Chem Biol Interact. 1974 Nov;9(5):317-26. No abstract available.

PMID:
4611655
26.
27.

Some properties of "K-region" epoxides of polycyclic aromatic hydrocarbons.

Swaisland AJ, Grover PL, Sims P.

Biochem Pharmacol. 1973 Jul 1;22(13):1547-56. No abstract available.

PMID:
4125777

Supplemental Content

Loading ...
Support Center